-
Mashup Score: 4
Barinthus Biotherapeutics has hit the primary endpoint of a phase 1b/2 trial by showing its treatment for high-risk human papillomavirus (hrHPV)-associated cervical cancer is safe. | Barinthus Biotherapeutics has hit the primary endpoint of a phase 1b/2 trial by showing its treatment for high risk human papillomavirus-associated cervical cancer is safe. But the failure to prove the therapy actually works has left the biotech mulling how to take the candidate further.
Source: www.fiercebiotech.comCategories: General Medicine News, Infectious DiseaseTweet
-
Mashup Score: 0
The FDA has handed out groundbreaking green lights to a pair of novel antibacterial coatings that each aim to keep implants as clean as possible during their short trip in the operating room from p | Though the initial green lights cover spine and orthopedic hardware, Orthobond and Onkos Surgical said their respective disinfectants could shield a wide variety of implants.
Source: www.fiercebiotech.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 2
The FDA has handed out groundbreaking green lights to a pair of novel antibacterial coatings that each aim to keep implants as clean as possible during their short trip in the operating room from p | Though the initial green lights cover spine and orthopedic hardware, Orthobond and Onkos Surgical said their respective disinfectants could shield a wide variety of implants.
Source: www.fiercebiotech.comCategories: General Medicine News, Infectious DiseaseTweet
-
Mashup Score: 0Precision medicine approach combining AI, DNA and drug testing shows gains against relapsed childhood cancers - 17 day(s) ago
Researchers have demonstrated that a functional precision medicine approach—combining artificial intelligence, DNA sequencing, mutation mapping and drug sensitivity testing—could feasibly help tack | The process, being developed by First Ascent Biomedical, showed promise in a small study published this week in Nature Medicine.
Source: www.fiercebiotech.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 3Former bluebird execs hope to fly new startup to 'cutting edge' of gene therapy delivery tech - 17 day(s) ago
The untapped potential of gene editing therapies comes down to one major challenge: getting gene editors safely and efficiently into cells. | The untapped potential of gene editing therapies comes down to one major challenge: getting gene editors safely and efficiently into cells. Now, a new startup founded by two genetic medicine luminaries and run by former executives from bluebird bio is officially emerging from stealth mode to reveal its solutions to the industry.
Source: www.fiercebiotech.comCategories: General Medicine News, Future of MedicineTweet
-
Mashup Score: 1Enlivex defends sepsis data that sank stock, shifting focus from mortality to subgroup analysis - 17 day(s) ago
Enlivex Therapeutics had a message Friday for investors who halved its share price: You’re misreading our data. | Enlivex Therapeutics had a message Friday for investors who halved its share price: You’re misreading our data. The cell therapy developer blamed imbalances between cohorts for the mixed results—and contended the effect on a small subgroup of sepsis patients suggests the candidate has a future.
Source: www.fiercebiotech.comCategories: General Medicine News, Infectious DiseaseTweet
-
Mashup Score: 21AACR: Cancer vaccines get a reintroduction as readouts support 'path forward' for the tech - 19 day(s) ago
A session at the American Association for Cancer Research (AACR) annual meeting posed a key question: Are cancer vaccines ready for prime time? | A session at the American Association for Cancer Research annual meeting asked a key question: Are cancer vaccines ready for prime time? If you ask Scott Kopetz, M.D., Ph.D., of the University of Texas MD Anderson Cancer Center, the answer is a quick yes.
Source: www.fiercebiotech.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 2BrainStorm, plotting Lazerus-like recovery, aligns with FDA on design of phase 3b ALS trial - 19 day(s) ago
BrainStorm Cell Therapeutics is hauling itself off the mat for another run at amyotrophic lateral sclerosis (ALS). | BrainStorm Cell Therapeutics is hauling itself off the mat for another run at amyotrophic lateral sclerosis. A piece of the latest comeback strategy slotted into place Tuesday when the biotech revealed a written agreement with the FDA on the design of a phase 3b trial.
Source: www.fiercebiotech.comCategories: General Medicine News, Rare DiseaseTweet
-
Mashup Score: 12
Roche raised the curtain on its upcoming continuous glucose monitoring system featuring artificial intelligence-powered forecasts of blood sugar highs and lows. | At the International Conference on Advanced Technologies and Treatments for Diabetes, being held this week in Florence, Italy, the company put forward the first accuracy data for its new Accu-Chek SmartGuide sensor and apps.
Source: www.fiercebiotech.comCategories: General Medicine News, EndocrinologyTweet
-
Mashup Score: 2
CureVac and GSK have been racing behind Moderna to try to get the first mRNA flu vaccine to market. But, now, the European partners have come up against the exact same problem as their U.S. | CureVac and GSK have been racing behind Moderna to try and get the first mRNA flu vaccine to market. But now the European partners have come up against the exact same problem as their U.S. competitor when it comes to the “historically challenging” B strains of influenza.
Source: www.fiercebiotech.comCategories: General Medicine News, Infectious DiseaseTweet
“VTP-200 is an immunotherapeutic combo regimen that involves patients receiving an initial dose using the ChAdOx vector & a 2nd dose using the MVA vector. Both doses encode the same HPV antigens, w/ the aim of producing an antigen-specific T-cell immune” https://t.co/WQomUIsKBo